$SENS
Senseonics Holdings, Inc. Stock $sens

$sens Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022002569 Filed on March 01, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$4.008M	$13.68M	$3.885M
YoY Change	3.17%	176.32%	-56.61%
Cost Of Revenue	$4.491M	$14.49M	$1.309M
YoY Change	243.09%	-35.08%	-92.39%
Gross Profit	-$483.0K	-$811.0K	$2.576M
YoY Change	-118.75%	-95.33%	-131.25%
Gross Profit Margin	-12.05%	-5.93%	66.31%
Selling, General & Admin	$5.807M	$27.02M	$8.195M
YoY Change	-29.14%	-34.65%	-51.48%
% of Gross Profit			318.13%
Research & Development	$7.655M	$27.22M
YoY Change		33.33%
% of Gross Profit
Depreciation & Amortization	$321.0K	$1.239M	$288.0K
YoY Change	11.46%	8.59%	-56.76%
% of Gross Profit			11.18%
Operating Expenses	$13.46M	$54.24M	$12.88M
YoY Change	4.5%	-12.19%	-51.63%
Operating Profit	-$13.95M	-$57.18M	-$10.31M
YoY Change	35.31%	-27.74%	-70.45%
Interest Expense	$97.83M	$16.72M	-$76.04M
YoY Change	-228.66%	3.42%	8560.14%
% of Operating Profit
Other Income/Expense, Net	$553.0K	-$245.3M	-$12.30M
YoY Change	-104.5%	155.41%	-8639.58%
Pretax Income	$84.43M	-$302.5M	-$101.6M
YoY Change	-183.08%	72.68%	185.39%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	$84.43M	-$302.5M	-$101.6M
YoY Change	-183.08%	72.66%	185.39%
Net Earnings / Revenue	2106.61%	-2212.07%	-2616.01%
Basic Earnings Per Share		-$0.72
Diluted Earnings Per Share	$188.9K	-$0.72	-$405.1K
COMMON SHARES
Basic Shares Outstanding	446.0M	422.3M	245.7M
Diluted Shares Outstanding		422.3M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$181.8M	$129.9M	$18.01M
YoY Change	909.65%	621.5%	-81.23%
Cash & Equivalents	$33.46M	$29.20M	$18.01M
Short-Term Investments	$148.3M	$96.45M	$0.00
Other Short-Term Assets	$5.775M	$5.775M	$3.974M
YoY Change	45.32%	45.32%	-11.92%
Inventory	$6.316M	$6.316M	$5.281M
Prepaid Expenses
Receivables	$1.973M	$1.973M	$2.986M
Other Receivables	$443.0K	$443.0K	$0.00
Total Short-Term Assets	$144.4M	$144.4M	$30.25M
YoY Change	377.46%	377.46%	-76.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.308M	$1.308M	$1.557M
YoY Change	-15.99%	-64.5%	-22.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$51.88M	$51.88M	$1.886M
YoY Change	2650.9%	2650.9%
Other Assets	$1.325M	$1.325M	$101.0K
YoY Change	1211.88%	1211.88%	-96.68%
Total Long-Term Assets	$54.52M	$54.52M	$5.672M
YoY Change	861.12%	861.12%	12.47%
TOTAL ASSETS
Total Short-Term Assets	$144.4M	$144.4M	$30.25M
Total Long-Term Assets	$54.52M	$54.52M	$5.672M
Total Assets	$198.9M	$198.9M	$35.92M
YoY Change	453.84%	453.84%	-72.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.204M	$1.204M	$1.762M
YoY Change	-31.67%	-31.67%	-58.88%
Accrued Expenses	$14.26M	$14.26M	$11.52M
YoY Change	23.76%	23.76%	-38.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.926M	$2.926M	$3.202M
YoY Change	-8.62%	-8.62%	-96.91%
Total Short-Term Liabilities	$18.39M	$18.39M	$16.64M
YoY Change	10.55%	10.55%	-86.87%
LONG-TERM LIABILITIES
Long-Term Debt	$59.80M	$59.80M	$57.22M
YoY Change	4.51%	4.51%	384.88%
Other Long-Term Liabilities	$579.0K	$306.3M	$1.483M
YoY Change	-60.96%	196.38%	-34.9%
Total Long-Term Liabilities	$579.0K	$366.1M	$1.483M
YoY Change	-60.96%	128.01%	-34.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.39M	$18.39M	$16.64M
Total Long-Term Liabilities	$579.0K	$366.1M	$1.483M
Total Liabilities	$384.5M	$384.5M	$177.2M
YoY Change	116.98%	116.98%	25.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$951.0M		-$648.5M
YoY Change	46.64%		37.01%
Common Stock	$447.0K		$266.0K
YoY Change	68.05%		31.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$185.5M	-$185.5M	-$144.1M
YoY Change
Total Liabilities & Shareholders Equity	$198.9M	$198.9M	$35.92M
YoY Change	453.84%	453.84%	-72.95%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$84.43M	-$302.5M	-$101.6M
YoY Change	-183.08%	72.66%	185.39%
Depreciation, Depletion And Amortization	$321.0K	$1.239M	$288.0K
YoY Change	11.46%	8.59%	-56.76%
Cash From Operating Activities	-$11.80M	-$56.08M	-$8.248M
YoY Change	43.1%	-16.83%	-76.13%
INVESTING ACTIVITIES
Capital Expenditures	-$135.0K	-$210.0K	$0.00
YoY Change		16.02%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$6.379M	-$148.5M
YoY Change
Cash From Investing Activities	$6.244M	-$148.7M	$0.00
YoY Change		82081.77%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-7.191M	220.1M	61.00K
YoY Change	-11888.52%	-2272.59%	369.23%
NET CHANGE
Cash From Operating Activities	-11.80M	-56.08M	-8.248M
Cash From Investing Activities	6.244M	-148.7M	0.000
Cash From Financing Activities	-7.191M	220.1M	61.00K
Net Change In Cash	-12.75M	15.26M	-8.187M
YoY Change	55.73%	-119.63%	-76.37%
FREE CASH FLOW
Cash From Operating Activities	-$11.80M	-$56.08M	-$8.248M
Capital Expenditures	-$135.0K	-$210.0K	$0.00
Free Cash Flow	-$11.67M	-$55.87M	-$8.248M
YoY Change	41.46%	-16.91%	-76.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001616543
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.senseonics.com/20211231#DepositsAndOtherAssetsNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.senseonics.com/20211231#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.senseonics.com/20211231#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://www.senseonics.com/20211231#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	265582688
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	447282263
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	447282263
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	265582688
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3000
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-37717
CY2021	dei	Entity Registrant Name EntityRegistrantName	SENSEONICS HOLDINGS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1210911
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	20451 Seneca Meadows Parkway
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Germantown
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20876-7005
CY2021	dei	City Area Code CityAreaCode	301
CY2021	dei	Local Phone Number LocalPhoneNumber	515-7260
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	SENS
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1660000000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	463145879
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Tysons, VA
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33461000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18005000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	96445000
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	205000
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	565000
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1768000
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	2421000
CY2021Q4	us-gaap	Inventory Net InventoryNet	6316000
CY2020Q4	us-gaap	Inventory Net InventoryNet	5281000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6218000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3774000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	144413000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	30246000
CY2021Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	239000
CY2020Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	1886000
CY2021Q4	sens	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	1086000
CY2020Q4	sens	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	2229000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	51882000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1308000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1557000
CY2021Q4	us-gaap	Assets Assets	198928000
CY2020Q4	us-gaap	Assets Assets	35918000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1204000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1762000
CY2021Q4	sens	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	10667000
CY2020Q4	sens	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	11674000
CY2021Q4	sens	Accrued Liabilities And Other Liabilities Current From Related Parties AccruedLiabilitiesAndOtherLiabilitiesCurrentFromRelatedParties	3597000
CY2021Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	2926000
CY2020Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	3202000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18394000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16638000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	59798000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	57216000
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	236291000
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	62119000
CY2021Q4	sens	Long Term Options LongTermOptions	69401000
CY2020Q4	sens	Long Term Options LongTermOptions	39734000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	579000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1483000
CY2021Q4	us-gaap	Liabilities Liabilities	384463000
CY2020Q4	us-gaap	Liabilities Liabilities	177190000
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	3000
CY2020Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	2811000
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	2811000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	447282263
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	265582688
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	447000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	266000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	765215000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	504162000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-212000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-950985000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-648511000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-185535000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-144083000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	198928000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35918000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1394000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1368000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4924000
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	12281000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	3581000
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	16377000
CY2021	us-gaap	Revenues Revenues	13675000
CY2020	us-gaap	Revenues Revenues	4949000
CY2019	us-gaap	Revenues Revenues	21301000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14486000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22315000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	40749000
CY2021	us-gaap	Gross Profit GrossProfit	-811000
CY2020	us-gaap	Gross Profit GrossProfit	-17366000
CY2019	us-gaap	Gross Profit GrossProfit	-19448000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5483000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20550000
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	49555000
CY2021	sens	Selling And Marketing Expense From Related Parties SellingAndMarketingExpenseFromRelatedParties	2133000
CY2021	sens	Selling And Marketing Expense Including From Related Parties SellingAndMarketingExpenseIncludingFromRelatedParties	7616000
CY2020	sens	Selling And Marketing Expense Including From Related Parties SellingAndMarketingExpenseIncludingFromRelatedParties	20550000
CY2019	sens	Selling And Marketing Expense Including From Related Parties SellingAndMarketingExpenseIncludingFromRelatedParties	49555000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27217000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20413000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38430000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21538000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20801000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23229000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-57182000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-79130000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-130662000
CY2021	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	243000
CY2020	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	175000
CY2019	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1933000
CY2021	sens	Nonoperating Gain Loss Fair Value Adjustment NonoperatingGainLossFairValueAdjustment	-53152000
CY2020	sens	Nonoperating Gain Loss Fair Value Adjustment NonoperatingGainLossFairValueAdjustment	-30721000
CY2021	sens	Gains Losses On Extinguishment Of Debt And Gain Loss On Stock Conversion GainsLossesOnExtinguishmentOfDebtAndGainLossOnStockConversion	330000
CY2020	sens	Gains Losses On Extinguishment Of Debt And Gain Loss On Stock Conversion GainsLossesOnExtinguishmentOfDebtAndGainLossOnStockConversion	-21112000
CY2019	sens	Gains Losses On Extinguishment Of Debt And Gain Loss On Stock Conversion GainsLossesOnExtinguishmentOfDebtAndGainLossOnStockConversion	-398000
CY2020	sens	Loss On Issuance Of Debt And Other Issuance Cost LossOnIssuanceOfDebtAndOtherIssuanceCost	12706000
CY2021	us-gaap	Interest Expense InterestExpense	16720000
CY2020	us-gaap	Interest Expense InterestExpense	16167000
CY2019	us-gaap	Interest Expense InterestExpense	11799000
CY2020	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	1216000
CY2019	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3344000
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-174173000
CY2020	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-11641000
CY2019	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	29232000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1647000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2339000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-173000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-311000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-511000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-245292000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-96038000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15113000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-302474000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-175168000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-115549000
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-212000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-212000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-302686000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-175168000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-115549000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	422321023
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	227912358
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188754160
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	422321023
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	227912358
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188754160
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	71261000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26757000
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	108000
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	8052000
CY2019	sens	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options And Restricted Stock Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsAndRestrictedStockRequisiteServicePeriodRecognition	722000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-115549000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-8649000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-26000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	576000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	27259000
CY2020	sens	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options And Restricted Stock Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsAndRestrictedStockRequisiteServicePeriodRecognition	7314000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4611000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-175168000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-144083000
CY2021	sens	Shares Issued During Period Value Conversion Of Temporary Equity SharesIssuedDuringPeriodValueConversionOfTemporaryEquity	45565000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200365000
CY2020	us-gaap	Profit Loss ProfitLoss	-175168000
CY2019	us-gaap	Profit Loss ProfitLoss	-115549000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1239000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1141000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1001000
CY2021	sens	Amortization Of Financing Costs Discounts And Deferred Costs AmortizationOfFinancingCostsDiscountsAndDeferredCosts	8462000
CY2020	sens	Amortization Of Financing Costs Discounts And Deferred Costs AmortizationOfFinancingCostsDiscountsAndDeferredCosts	10977000
CY2019	sens	Amortization Of Financing Costs Discounts And Deferred Costs AmortizationOfFinancingCostsDiscountsAndDeferredCosts	8457000
CY2021	sens	Fair Value Adjustment Derivative Liability FairValueAdjustmentDerivativeLiability	174173000
CY2020	sens	Fair Value Adjustment Derivative Liability FairValueAdjustmentDerivativeLiability	11641000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4993000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6501000
CY2021	sens	Issued Common Stock For Vested Rsus And Espp Purchase IssuedCommonStockForVestedRsusAndEsppPurchase	74000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5293000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9029000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-302474000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-212000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-185535000
CY2021	us-gaap	Profit Loss ProfitLoss	-302474000
CY2019	sens	Fair Value Adjustment Derivative Liability FairValueAdjustmentDerivativeLiability	-29232000
CY2021	sens	Nonoperating Gain Loss Fair Value Adjustment NonoperatingGainLossFairValueAdjustment	-53152000
CY2020	sens	Nonoperating Gain Loss Fair Value Adjustment NonoperatingGainLossFairValueAdjustment	-30721000
CY2021	sens	Gains Losses On Extinguishment Of Debt And Gain Loss On Stock Conversion GainsLossesOnExtinguishmentOfDebtAndGainLossOnStockConversion	330000
CY2020	sens	Gains Losses On Extinguishment Of Debt And Gain Loss On Stock Conversion GainsLossesOnExtinguishmentOfDebtAndGainLossOnStockConversion	-21112000
CY2019	sens	Gains Losses On Extinguishment Of Debt And Gain Loss On Stock Conversion GainsLossesOnExtinguishmentOfDebtAndGainLossOnStockConversion	-398000
CY2020	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	12706000
CY2021	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	518000
CY2021	sens	Impairment Of Options ImpairmentOfOptions	1647000
CY2020	sens	Impairment Of Options ImpairmentOfOptions	2339000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9029000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	7314000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	8052000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-10000
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-181000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-310000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1013000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7393000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3282000
CY2021	sens	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	2444000
CY2020	sens	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-737000
CY2019	sens	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	527000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1036000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-11648000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6698000
CY2021	sens	Increase Decrease In Deposit Assets And Other Assets IncreaseDecreaseInDepositAssetsAndOtherAssets	164000
CY2020	sens	Increase Decrease In Deposit Assets And Other Assets IncreaseDecreaseInDepositAssetsAndOtherAssets	-117000
CY2019	sens	Increase Decrease In Deposit Assets And Other Assets IncreaseDecreaseInDepositAssetsAndOtherAssets	3442000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-559000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2522000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-122000
CY2021	sens	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	1314000
CY2020	sens	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	-6585000
CY2019	sens	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	4827000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-628000
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	372000
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-379000
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	388000
CY2020	sens	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-795000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56078000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67422000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136047000
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	210000
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	181000
CY2019	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1045000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	154514000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5975000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-148749000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1045000
CY2021	sens	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	200365000
CY2020	sens	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	-26000
CY2019	sens	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	26757000
CY2021	sens	Proceeds From Exercise Of Stock Options Stock Warrants And Espp Purchases ProceedsFromExerciseOfStockOptionsStockWarrantsAndEsppPurchases	5066000
CY2020	sens	Proceeds From Exercise Of Stock Options Stock Warrants And Espp Purchases ProceedsFromExerciseOfStockOptionsStockWarrantsAndEsppPurchases	576000
CY2019	sens	Proceeds From Exercise Of Stock Options Stock Warrants And Espp Purchases ProceedsFromExerciseOfStockOptionsStockWarrantsAndEsppPurchases	108000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5293000
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	55971000
CY2019	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	127000000
CY2020	sens	Payments Of Notes Payable Issuance Costs PaymentsOfNotesPayableIssuanceCosts	601000
CY2019	sens	Payments Of Notes Payable Issuance Costs PaymentsOfNotesPayableIssuanceCosts	4301000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2049000
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	22783000
CY2019	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	722000
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	2838000
CY2020	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	66050000
CY2019	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	15000000
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	37000000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	220083000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10130000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96237000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15256000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-77733000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40855000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18205000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95938000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136793000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33461000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18205000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95938000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7822000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4726000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	5233000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2974000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	30000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000
CY2021	sens	Common Stock Issued Converted From Preferred Shares CommonStockIssuedConvertedFromPreferredShares	54166000
CY2021	sens	Common Stock Issued1 CommonStockIssued1	4925000
CY2020	sens	Common Stock Issued1 CommonStockIssued1	227000
CY2020	sens	Proceeds From Issuance Of Common Stock And Warrants In Connection With Highbridge Transactions ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithHighbridgeTransactions	55303000
CY2020	sens	Proceeds From Issuance Of Common Stock In Connection With Energy Capital ProceedsFromIssuanceOfCommonStockInConnectionWithEnergyCapital	3399000
CY2020	us-gaap	Notes Reduction NotesReduction	24000000
CY2020	us-gaap	Notes Issued1 NotesIssued1	15675000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Organization</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Senseonics Holdings, Inc., a Delaware corporation, is a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Senseonics, Incorporated is a wholly owned subsidiary of Senseonics Holdings and was originally incorporated on October 30, 1996 and commenced operations on January 15, 1997. Senseonics Holdings and Senseonics, Incorporated are hereinafter collectively referred to as the “Company” unless otherwise indicated or the context otherwise requires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-302500000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-951000000.0
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	181800000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, recoverability of long-lived assets, deferred taxes and valuation allowances, derivative assets and liabilities, obsolete inventory, warranty obligations, variable consideration related to revenue, depreciable lives of property and equipment, and accruals for clinical study costs, which are accrued based on estimates of work performed under contract. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses. Actual results could differ from those estimates; however, management does not believe that such differences would be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-200000
CY2021Q4	us-gaap	Cash Cash	4264000
CY2020Q4	us-gaap	Cash Cash	18002000
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	29197000
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	3000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33461000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18005000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33461000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18005000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33461000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18205000
CY2019	sens	Number Of Geographical Markets NumberOfGeographicalMarkets	2
CY2020	sens	Number Of Geographical Markets NumberOfGeographicalMarkets	2
CY2021	sens	Number Of Geographical Markets NumberOfGeographicalMarkets	2
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><b style="font-weight:bold;">Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">In connection with the Company’s issuance of the convertible senior subordinated notes due 2023 (the “2023 Notes”), in January 2018, the Company bifurcated the embedded conversion option, along with the interest make-whole </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">provision and make-whole fundamental change provision, and recorded the embedded conversion option as a derivative liability in the Company’s consolidated balance sheets in accordance with Accounting Standards Codification (“ASC”) Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">In July 2019, the Company issued $82.0 million in aggregate principal amount of convertible senior subordinated notes due 2025 (the “2025 Notes). In connection with the 2025 Notes, the Company bifurcated the embedded conversion option along with the fundamental change make-whole provision and the cash settled fundamental make-whole shares provision, and recorded the fair value of these embedded features as a derivative liability in the Company’s consolidated balance sheets in accordance with ASC Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:36pt;margin:0pt;">On April 21, 2020, the Company entered into the Highbridge Loan Agreement, in which an aggregate principal amount of $15.0 million was borrowed through the issuance and sale of the First Lien Notes and issued 1,500,000 shares of its common stock to the Lenders as a commitment fee. The First Lien Notes also contained redemption features that were evaluated for bifurcation as separate derivative instruments including the permitted prepayment put option, the mandatory accelerated redemption and the mandatory redemption and reinvestment upon an asset sale. The Company recorded the fair value of the embedded features in the amount of $1.0 million as a debt premium and derivative asset in its consolidated balance sheets in accordance with ASC Topic 815, Derivatives and Hedging. The derivative was adjusted to fair value at each reporting period, with the change recorded in change in fair value of derivatives that is a component of other income (expense) in its consolidated statements of operations and comprehensive loss. On August 14, 2020, the Company prepaid the First Lien Notes in full, including the discounted prepayment premium, in the amount of approximately $17.6 million and recognized a loss on extinguishment in the amount of $0.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:36pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:36pt;margin:0pt;">On April 21, 2020, the Company entered into a Note Purchase and Exchange Agreement with certain funds managed by Highbridge providing for the exchange (the “Exchange”) of $24.0 million aggregate principal amount of the outstanding 2025 Notes for (i) $15.7 million aggregate principal amount of newly issued Second Lien Notes, (ii) 11,026,086 shares of common stock, (iii) warrants to purchase up to 4,500,000 shares of common stock at an exercise price of $0.66 per share, and (iv) $0.3 million in accrued and unpaid interest on the 2025 Notes being exchanged. On August 9, 2020, the Company entered into a First Amendment to Note Purchase and Exchange Agreement with Highbridge (as amended by the Amendment, the “Exchange Agreement”). The Second Lien Notes also contained redemption features that were evaluated for bifurcation as separate derivative instruments including the permitted prepayment put option, the mandatory accelerated redemption and the mandatory redemption and reinvestment upon an asset sale. Unlike the First Lien Notes, the Second Lien Notes also permit voluntary conversion at the option of the holder as described above. The Company recorded the fair value of these embedded features in the amount of $1.9 million as a derivative asset in its consolidated balance sheets in accordance with ASC Topic 815, Derivatives and Hedging. The derivative was adjusted to fair value at each reporting period, with the change in the fair value recorded in change in fair value of derivatives that is a component of other income (expense) in its consolidated statement of operations and comprehensive loss. During the fiscal year ended December 31, 2020, Highbridge elected to convert the full $15.7 million of outstanding principal on the Second Lien Notes for issuance of 42,776,936 shares of common stock, which included prepayment premiums and were based off of its election of PIK interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">In August 2020, the Company issued $35.0 million in aggregate principal amount of convertible senior secured notes due PHC, or the PHC Notes. The Note Purchase Agreement also contained several provisions requiring bifurcation as a separate derivative liability including an embedded conversion feature, mandatory prepayment upon event of default that constitutes a breach of the minimum revenue financial covenant, optional redemption upon an event of default, change in interest rate after PMA approval and default interest upon an event of default. On the date of issuance, the Company recorded the fair value of the embedded features in the amount of $25.8 million as a derivative liability in the Company’s consolidated balance sheets in accordance with ASC Topic 815, Derivatives and Hedging.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">The financial instruments above are remeasured at the end of each reporting period with changes in fair value recorded in the consolidated statements of operations and comprehensive loss in other income (expense) as a change in fair value of the derivative liability.</p>
CY2021Q4	us-gaap	Time Sharing Transactions Allowance For Uncollectible Accounts TimeSharingTransactionsAllowanceForUncollectibleAccounts	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Warranty Obligation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company provides a warranty of one year on its smart transmitters. Additionally, the Company may also replace Eversense system components that do not function in accordance with the product specifications. Estimated replacement costs are recorded at the time of shipment as a charge to cost of sales in the consolidated statement of operations and are developed by analyzing product performance data and historical replacement experience, including comparing actual return management authorizations to revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At December 31, 2021 and December 31, 2020, the warranty reserve was $0.7 million and $0.6 million, respectively. The following table provides a reconciliation of the change in estimated warranty liabilities for the years ended December 31, 2021 and 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:52.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at beginning of the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 646</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,197</p></td></tr><tr><td style="vertical-align:bottom;width:52.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for warranties during the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 781</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (266)</p></td></tr><tr><td style="vertical-align:bottom;width:52.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements made during the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (704)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,285)</p></td></tr><tr><td style="vertical-align:bottom;width:52.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at end of the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 723</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 646</p></td></tr></table>
CY2021	sens	Product Warranty Term ProductWarrantyTerm	P1Y
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	700000
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	600000
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	646000
CY2019Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2197000
CY2021	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	781000
CY2020	sens	Standard Product Warranty Provision Reduction StandardProductWarrantyProvisionReduction	266000
CY2021	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	704000
CY2020	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	1285000
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	723000
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	646000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	149382078
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	173222308
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	99653576
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	148539000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	212000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	148327000
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	0
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	96479000
CY2021Q4	sens	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo	45478000
CY2021Q4	sens	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree	3552000
CY2021Q4	sens	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearThree	3030000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	148539000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1012000
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	203000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3770000
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2626000
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	1534000
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	2452000
CY2021Q4	us-gaap	Inventory Net InventoryNet	6316000
CY2020Q4	us-gaap	Inventory Net InventoryNet	5281000
CY2021Q4	sens	Prepaid Contract Manufacturing Current PrepaidContractManufacturingCurrent	5036000
CY2020Q4	sens	Prepaid Contract Manufacturing Current PrepaidContractManufacturingCurrent	3324000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3774000
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	443000
CY2021Q4	sens	Prepaid Information Technology And Software Costs Current PrepaidInformationTechnologyAndSoftwareCostsCurrent	225000
CY2020Q4	sens	Prepaid Information Technology And Software Costs Current PrepaidInformationTechnologyAndSoftwareCostsCurrent	150000
CY2021Q4	sens	Prepaid Clinical And Preclinical Costs PrepaidClinicalAndPreclinicalCosts	142000
CY2020Q4	sens	Prepaid Clinical And Preclinical Costs PrepaidClinicalAndPreclinicalCosts	11000
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	105000
CY2020Q4	us-gaap	Prepaid Rent PrepaidRent	102000
CY2021Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	98000
CY2020Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	53000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	74000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	50000
CY2021Q4	sens	Research And Development ResearchAndDevelopment	39000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	29000
CY2021Q4	sens	Prepaid Corporate And Finance Consulting Expenses PrepaidCorporateAndFinanceConsultingExpenses	27000
CY2020Q4	sens	Prepaid Corporate And Finance Consulting Expenses PrepaidCorporateAndFinanceConsultingExpenses	84000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6218000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2838000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2659000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1530000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1102000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1308000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1557000
CY2021	us-gaap	Depreciation Depreciation	500000
CY2020	us-gaap	Depreciation Depreciation	400000
CY2019	us-gaap	Depreciation Depreciation	500000
CY2020	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	300000
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	1400000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1500000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	900000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	9475000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	900000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6882000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3484000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4344000
CY2021Q4	sens	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	2145000
CY2020Q4	sens	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	842000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2144000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1773000
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1962000
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	615000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1697000
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	646000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1011000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	880000
CY2021Q4	sens	Accrued Contract Manufacturing Costs Current AccruedContractManufacturingCostsCurrent	914000
CY2020Q4	sens	Accrued Contract Manufacturing Costs Current AccruedContractManufacturingCostsCurrent	1421000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	904000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	794000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	151000
CY2020Q4	sens	Accrued Patient Access And Incentive Programs Current AccruedPatientAccessAndIncentiveProgramsCurrent	208000
CY2021Q4	sens	Accrued Liabilities And Other Liabilities Including Related Party Current AccruedLiabilitiesAndOtherLiabilitiesIncludingRelatedPartyCurrent	14264000
CY2020Q4	sens	Accrued Liabilities And Other Liabilities Including Related Party Current AccruedLiabilitiesAndOtherLiabilitiesIncludingRelatedPartyCurrent	11674000
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	500000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	800000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	299000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3183000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	19839000
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7564000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	8433000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	212000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-21112000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	37321000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	821000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	904000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	579000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1483000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1002000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	600000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1602000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	119000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1483000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	900000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.53
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000
CY2020Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4800000
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24218000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.16
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2926000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	15700000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	35000000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	51199000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	104825000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	447282263
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	265582688
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	469000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.54
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	201000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8711000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.95
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15775000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.16
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M3D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	224000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.98
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2355000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.61
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	260000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.06
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13384000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M15D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13384000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.38
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	11700000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.36
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y5M15D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.97
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.33
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.60
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2354566
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	201447
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	87591
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4400000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3100000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5800000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5100000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5700000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.58
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.59
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.61
CY2021	sens	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	1.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.89
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	125242000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	115531000
CY2021Q4	sens	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	7315000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0.56
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q4	sens	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	8477000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	11251000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10208000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2061000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4056000
CY2021Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	8853000
CY2020Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	9222000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	912000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1096000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	155634000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	148590000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	146463000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	136031000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9171000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12559000
CY2021Q4	sens	Deferred Tax Liability Amortization Right Of Use Asset DeferredTaxLiabilityAmortizationRightOfUseAsset	318000
CY2020Q4	sens	Deferred Tax Liability Amortization Right Of Use Asset DeferredTaxLiabilityAmortizationRightOfUseAsset	477000
CY2021Q4	sens	Deferred Tax Liability Amortization Of Debt Discount DeferredTaxLiabilityAmortizationOfDebtDiscount	8853000
CY2020Q4	sens	Deferred Tax Liability Amortization Of Debt Discount DeferredTaxLiabilityAmortizationOfDebtDiscount	12082000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9171000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	12559000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10400000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22800000
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	585100000
CY2021Q4	sens	Operating Loss Carryforwards Subject To Expiry OperatingLossCarryforwardsSubjectToExpiry	198500000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0157
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0034
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0046
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0132
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0218
CY2021	sens	Income Tax Expense Benefit Continuing Operations Share Based Compensation IncomeTaxExpenseBenefitContinuingOperationsShareBasedCompensation	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0160
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0232
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0085
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0217
CY2021	sens	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt And Other Issuance Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtAndOtherIssuanceCostPercent	-0.1709
CY2020	sens	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt And Other Issuance Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtAndOtherIssuanceCostPercent	-0.1115
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0078
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0033
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0044
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0091
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0322
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1134
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2081
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2552000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2351000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1969000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	267000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	201000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	396000
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	6000
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	14000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2813000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2552000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2351000
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0

Files In Submission

Name	View Source	Status
0001558370-22-002569-index-headers.html	Edgar Link	pending
0001558370-22-002569-index.html	Edgar Link	pending
0001558370-22-002569.txt	Edgar Link	pending
0001558370-22-002569-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sens-20211231.xsd	Edgar Link	pending
sens-20211231x10k.htm	Edgar Link	pending
sens-20211231x10k004.jpg	Edgar Link	pending
sens-20211231x10k005.jpg	Edgar Link	pending
sens-20211231x10k_htm.xml	Edgar Link	completed
sens-20211231xex23d1.htm	Edgar Link	pending
sens-20211231xex31d1.htm	Edgar Link	pending
sens-20211231xex31d2.htm	Edgar Link	pending
sens-20211231xex32d1.htm	Edgar Link	pending
sens-20211231_cal.xml	Edgar Link	unprocessable
sens-20211231_def.xml	Edgar Link	unprocessable
sens-20211231_lab.xml	Edgar Link	unprocessable
sens-20211231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SENS
Senseonics Holdings, Inc. Stock $sens

2021 Q4 Form 10-K Financial Statement

#000155837022002569 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SENS Senseonics Holdings, Inc. Stock $sens

2021 Q4 Form 10-K Financial Statement

#000155837022002569 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SENS
Senseonics Holdings, Inc. Stock $sens